Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 12'th Feb 2026
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
08:00am, Wednesday, 04'th Feb 2026
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data d
Caribou Biosciences (NASDAQ:CRBU) Shares Up 0.6% – Should You Buy?
02:26am, Wednesday, 14'th Jan 2026
Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report)'s stock price was up 0.6% during trading on Tuesday. The company traded as high as $1.64 and last traded at $1.59. Approximately 1,035,077 sh
Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 13'th Jan 2026
Caribou Biosciences (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
06:00am, Wednesday, 24'th Dec 2025
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The U. S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], dri
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
04:05pm, Monday, 01'st Dec 2025
BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hos
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates
06:30pm, Wednesday, 12'th Nov 2025
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.38 per share a year ago.
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 12'th Nov 2025
Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class
Caribou Biosciences to Participate in Upcoming Investor Conferences
05:15pm, Monday, 03'rd Nov 2025
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>
11:48am, Monday, 03'rd Nov 2025
Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-ter
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
07:00am, Monday, 03'rd Nov 2025
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinic
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hol
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
04:05pm, Monday, 25'th Aug 2025
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Tuesday, 12'th Aug 2025
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company's curr
